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In the present study, we microinjected fluorescently labelled liver
bovine ACBP (acyl-CoA-binding protein) [FACI-50 (fluorescent
acyl-CoA indicator-50)] into HeLa and BMGE (bovine mammary
gland epithelial) cell lines to characterize the localization and
dynamics of ACBP in living cells. Results showed that ACBP
targeted to the ER (endoplasmic reticulum) and Golgi in a
ligand-binding-dependent manner. A variant Y28F/K32A-FACI-
50, which is unable to bind acyl-CoA, did no longer show
association with the ER and became segregated from the Golgi,
as analysed by intensity correlation calculations. Depletion of
fatty acids from cells by addition of FAFBSA (fatty-acid-free
BSA) significantly decreased FACI-50 association with the Golgi,
whereas fatty acid overloading increased Golgi association,
strongly supporting that ACBP associates with the Golgi in
a ligand-dependent manner. FRAP (fluorescence recovery after
photobleaching) showed that the fatty-acid-induced targeting of
FACI-50 to the Golgi resulted in a 5-fold reduction in FACI-50
mobility. We suggest that ACBP is targeted to the ER and Golgi
in a ligand-binding-dependent manner in living cells and propose
that ACBP may be involved in vesicular trafficking.
Key words: acyl-CoA-binding protein (ACBP), confocal mi-
croscopy, endoplasmic reticulum, Golgi, trafficking, two-photon
excitation fluorescence recovery after photobleaching (FRAP).
INTRODUCTION
ACBP (acyl-CoA-binding protein) is a highly conserved protein
from protozoa to humans [1], which suggests that the protein is
required for very basic functions conserved throughout the
eukaryotic kingdom. Our understanding of the function of ACBP
is still incomplete. In vitro studies have shown that ACBP de-
sorbs acyl-CoA esters embedded in immobilized synthetic
lipid membranes and donates acyl-CoA to β-oxidation in
mitochondria or glycerolipid synthesis in microsomes [2,3],
suggesting that ACBP acts as an acyl-CoA transporter. Depletion
of the ACBP homologue, Acb1p, from the yeast Saccharomyces
cerevisiae results in strongly reduced growth, accumulation of
large amounts of cytoplasmic vesicles and multilayered plasma
membranes and fragmented vacuoles [4]. The vacuoles isolated
from the Acb1p-depleted strain lack important SNARE (soluble
N-ethylmaleimide-sensitive fusion protein-attachment protein
receptor) proteins and are unable to undergo homoeotypic fusion
[4]. This indicates that ACBP in the yeast may play a role
in vesicular trafficking. The Acb1p-depleted strain also shows
strongly reduced ceramide levels [5], indicating also a role for
ACBP in long-chain base synthesis and/or fatty acid elongation.
The finding that a Caenorhabditis elegans ACBP domain protein
MAA-1 is required for vesicular transport between the plasma
membrane and Golgi complex [6] further suggests a role of the
ACBP domain in vesicular trafficking. Experimental evidence
also suggests that ACBP plays a role in the regulation of HNF-4α
(hepatocyte nuclear factor-4α) [7] and further interacts with the
GABAAα1 (γ -aminobutyric acid Aα1) receptor subunit in rabbit
Mu¨ller cells [8]. Finally, ACBP has been shown to augment Bid-
induced mitochondrial damage and cell death by activating µ-
calpain [9].
Knowledge of the intracellular localization and movement of
ACBP in living cells would be of great value in assigning a
function to specific processes. Numerous in vitro studies have
been carried out to characterize the cellular localization of the
basal 82–92-residue ACBP (see [10] for a review). Subcellular
fractionation and immunohistochemical studies at the level of
electron microscopy report that ACBP can be found in the cytosol
associated with the smooth ER (endoplasmic reticulum), Golgi,
the outer membrane of mitochondria and around large cytoplasmic
vesicles [11–20]. Studies with the hornworm Manduca sexta
intestinal columnar cells and prothoracic gland ecdystereogenic
cells [19] and 3T3-L1 cells [21] show that ACBP, in addition to
being present in the cytosol, also appears in the nucleus.
The existing experimental results draw a very confused
picture of the possible intracellular localization of ACBP and
do not add to our understanding of the biological function
of the protein. A further complication in the interpretation of
the immunohistochemical and immunofluorescence data is that
ACBP cannot be fixed by conventional protein-denaturizing
methods. After denaturation with trichloroacetic acid, ACBP
readily re-dissolves in buffered solutions at neutral pH (J.S.
Hansen, N. J. Færgeman, B.B. Kragelund and J. Knudsen,
unpublished work). Hence, incomplete fixing of ACBP will result
in loss of ACBP during the immunostaining process.
To circumvent the above-mentioned problems, we have in the
present study visualized the cellular localization of ACBP in living
HeLa and BMGE (bovine mammary gland epithelial) cells by
using microinjection of fluorescently labelled bovine L-ACBP
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(liver-type ACBP) [FACI-50 (fluorescent acyl-CoA indicator-50)]
[22]. The results show that ACBP localizes to the ER and Golgi
complex in a ligand-dependent manner.
EXPERIMENTAL
Reagents
Nuclon angle-necked T75 culture flasks with filter caps were from
Nunc A/S (Roskilde, Denmark). Uncoated 50 mm glass-bottom
culture dishes were from MatTek (Ashland, MA, U.S.A.). DMEM
(Dulbecco’s modified Eagle’s medium) and prolactin [LTH
(luteotropic hormone)] were purchased from Sigma–Aldrich
Denmark (Brøndby, Denmark). FBS (foetal bovine serum),
MEM non-essential amino acids (100 times) solution, penicillin–
streptomycin [10000 units of penicillin (base) and 10000 µg
of streptomycin (base)/ml)] and L-glutamine 200 mM (100 times)
liquid were from Invitrogen (Taastrup, Denmark). Actrapid-
Insulin was from Novo Nordisk (Bagsværd, Denmark). Cortisol
was from SERVA Electrophoresis (Heidelberg, Germany). Sterile
Femtotips for microinjection and Femtotip microloaders (2–
20 µl) were from Eppendorf (Hamburg, Germany). The organelle-
specific fluorescent markers glibenclamide-BODIPY® (4,4-
difluoro-4-bora-3a,4a-diaza-s-indacene), MitoTracker Red CM-
H2XRos, LysoTracker Red DND-99, BODIPY® 493/503 neutral
lipid stain and BOPIPY® C5-ceramide complexed to BSA
were from Molecular Probes (Eugene, OR, U.S.A.). Badan (6-
bromoacetyl-2-dimethylaminonaphthalene) was from AnaSpec
(San Jose, CA, U.S.A.).
Site-directed mutagenesis, protein expression, purification and
badan labelling
Protein expression, purification and badan labelling of K50C-
ACBP and of M24C-ACBP to produce FACI-50 and FACI-24
respectively were carried out as previously described [23].
A variant of FACI-50 was constructed by introducing two
additional amino acid substitutions, Y28F and K32A, into the
existing K50C-ACBP plasmid. Site-directed mutagenesis was
carried out as previously described [24]. The primers used for
amplification of mutant bovine ACBP were 5′-GTAGTGAGA-
GAAGATGAACAACATTTC-3′ upstream (Y28F) and 5′-GCT-
CAAGCTACCGTTGGTGACATCAAC-3′ downstream (K32A).
Underlined bases indicate substitutions. Protein expression,
purification and badan labelling of bovine Y28F/K32A/K50C-
ACBP to produce Y28F/K32A-FACI-50 were carried out as for
FACI-50 [23].
Ligand binding studies of FACI-24, FACI-50 and Y28F/K32A-FACI-50
Dissociation constants of FACI-24, FACI-50 and Y28F/K32A-
FACI-50 were determined by isothermal microcalorimetry
essentially as described previously [25], except that the buffer
used was 20 mM Mes and 100 mM NaCl (pH 6.8).
Cell culture
HeLa cells were cultured in T75-culture flasks in DMEM with
penicillin (50 units/ml), streptomycin (50 µg/ml) (DMEMpen/strep),
10% (v/v) FBS, 0.1 mM non-essential amino acids and 10 mM
L-glutamine, in a humidified incubator at 37 ◦C in the presence
of 5% CO2. Medium was exchanged every 2 days and the cells
were subcultured at pre-confluent densities using 0.25% (w/v)
trypsin and 0.03% (w/v) EDTA in PBS (pH 7.4) (trypsin/EDTA
solution).
The BMGE cells originated from [26] and were kindly provided
by Professor Karsten Kristiansen (University of Southern
Denmark, Odense, Denmark). BMGE cells were cultured in T75-
culture flasks in DMEMpen/strep supplemented with 20% (v/v) FBS,
10 mM L-glutamine and insulin, cortisol and prolactin (1.0 µg/ml
each) in a humidified incubator at 37 ◦C in the presence of 5%
CO2 [26–28]. Cells were subcultured at pre-confluent densities
using trypsin/EDTA solution as described above.
Establishment of stable HeLa cell lines expressing GFP (green
fluorescent protein) or GFP–ACBP
The expression vector pEGFP-C1 with and without bovine liver
ACBP inserted were obtained from Professor Karsten Kristiansen
(University of Southern Denmark). On the day before transfection,
HeLa cells (2–6 × 106 cells) were plated on to 60 mm culture Petri
dishes containing 4 ml of DMEM supplemented with 10% FBS
and without antibiotics. HeLa cells were transfected with ACBP–
GFP vector or empty vector by using LipofectamineTM Plus
Reagent (Gibco Life Technologies, Rockville, MD, U.S.A.). The
transfection procedure was based on the manufacturers’ protocol
and adapted to 60 mm Petri dishes.
The transfected cell populations were maintained in complete
DMEM supplemented with 0.5 mg/ml G418, and cells were split
at a ratio of 1:10 twice a week. Cells transfected with expression
vector alone served as controls. For imaging experiments, cells
were grown on glass-bottom Petri dishes (MatTek).
Microinjection of HeLa and BMGE cells
For microinjection experiments, cells that had been grown to
subconfluence were dissociated from the plates by treatment
with trypsin/EDTA solution for 5 min at 37 ◦C. An aliquot of
1 × 105 cells was plated on to 50 mm diameter glass-bottom cul-
ture dishes (MatTek) and cultured to 70–80% confluence in
culture medium. Immediately before microinjection, the medium
was removed and replaced by C-Hepes buffer (20 mM Hepes,
140 mM NaCl, 5.5 mM glucose, 5 mM KCl, 1 mM NaH2PO4 and
1 mM MgSO4, pH 7.4) pre-equilibrated to 37 ◦C. Microinjection
was performed at room temperature (20 ◦C) using a microinjection
system consisting of an Eppendorf Microinjector 5242 and a
Micromanipulator 5170 (Eppendorf) attached to the side of
a Leica DMIRBE inverted microscope (Leica Microsystems,
Wetzlar, Germany). Microinjection was performed using a ×40
objective. HeLa and BMGE cells were microinjected with 200
and 400 µM respectively of FACI-50 or Y28F/K32A-FACI-50
dissolved in PBS (pH 7.4). The FACI solutions were centrifuged
(20000 g, 10 min and 4 ◦C) immediately before use. Sterile
Femtotips (Eppendorf) were back-filled with 2 µl of the FACI
solutions using Microloader tips (Eppendorf) and placed with a
45◦ angle over the Petri dish. Injection was executed with the
automatic inject function of the system, while injection time was
set to 0.5 s. The compensation pressure was set to 25 hPa and
injection pressure was adjusted to 100 hPa for HeLa cells and 130
hPa for BMGE cells respectively.
Double labelling experiments by confocal and two-photon laser
excitation microscopy
Microscopy was performed on a confocal microscope (model
LSM 510 META; Carl Zeiss MicroImaging, Jena, Germany)
using a ×40/1.2 NA (numerical aperture) Plan Apochromat
water-immersion lens unless otherwise stated. Acquisition was
performed using LSM 510 version 3.0 software (Carl Zeiss
MicroImaging).
For transfected cells, GFP fluorescence was excited at 488 nm
with a 30 mW Argon/2 laser, and images were collected using
a primary HFT 488 dichroic beam splitter and a 505 nm long
pass filter. The nuclei of GFP-transfected cells were identified by
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incubating cells for 60 min with 16 µM DAPI (4′,6-diamidino-2-
phenylindole) dissolved in C-Hepes buffer.
For FACI experiments, the 50 mm glass-bottom culture dishes
were, immediately after microinjection, transferred to a heated
(37.5 ◦C) microscope stage (TempControl Digital 37-2 device;
Warner Instruments) with a custom-made aluminium insert to fit
the 50 mm glass-bottom culture dishes. FACI-injected cells were
identified by shortly switching on/off a blue reflector by which
FACI-positive cells exhibited a bright green appearance.
For image acquisition, blue fluorophores (DAPI and FACIs)
were excited using two-photon excitation laser scanning
microscopy. Excitation was provided by a tuneable, broadband,
mode-locked titanium–sapphire Mai Tai laser (Spectra-Physics
Lasers) at 800 nm, which was reflected by a primary HFT KP
650 dichroic mirror, fluorescence was filtered with a secondary
NFT 490 dichroic mirror, and emission was recorded with a 435–
485 nm band-pass filter.
The ER was labelled by incubating cells with 2 µM
glibenclamide-BODIPY® in C-Hepes buffer at 37 ◦C in 5% CO2
for 30 min.
The Golgi complex was identified with BOPIPY® C5-ceramide
(Molecular Probes) as follows: cells were incubated with 5 µM
BODIPY® C5-ceramide complexed to BSA in C-Hepes buffer for
30 min at 37 ◦C. Cells were then washed with C-Hepes buffer and
incubated in DMEMpen/strep with serum for further 30 min at 37 ◦C.
Mitochondria were visualized using MitoTracker Red CM-
H2XRos with a final concentration of 0.5 µM in DMEMpen/strep
culture medium without serum. Cells were labelled for 45 min at
37 ◦C in 5% CO2.
Labelling of lysosomal vesicles was performed by incubating
cells with 75 nM LysoTracker Red DND-99 in DMEMpen/strep
without serum at 37 ◦C in 5% CO2 for 30 min.
Image acquisitions of glibenclamide-BODIPY®, BODIPY®
C5-ceramide, MitoTracker Red CM-H2XRos and LysoTracker
Red DND-99 were performed with excitation at 543 nm provided
by a 1 mV Helium/Neon1 (HeNe/1) laser, and emission was
collected using a primary HFT488/543/633 dichroic beam splitter,
a secondary NFT 545 dichroic mirror and a 565–615 nm band-
pass filter.
Lipid droplets and endogenous membranes were identified
using BODIPY® 493/503 neutral lipid stain. Labelling was
performed by incubating cells with 10 µg/ml of this lipophilic
dye dissolved in C-Hepes at 37 ◦C in 5% CO2 for 45 min. For
imaging, BODIPY® 493/503 was excited at 488 nm using a
30 mV Argon/2 laser and emission was collected using a primary
HFT 488 dichroic beam splitter and a 500–530 IR band pass filter.
For double labelling experiments, the two channels were
scanned alternately in a line-by-line fashion, having only one
laser line and one detector channel on at each time. Acquisition
of confocal fluorescence images was performed using a pinhole
diameter corresponding to 1 Airy unit unless otherwise stated.
Images were assessed using the LSM Browser (Carl Zeiss
MicroImaging) and processed using ImageJ open-source software
(http://rsb.info.nih.gov/ij).
Quantitative co-localization analysis
Co-localization of FACI-50 or Y28F/K32A-FACI-50 respectively
with organelle-specific dyes was performed using the ICA
(intensity correlation analysis) method described by Li et al.
[29]. The ICA method tests for co-localization by comparing
how the intensity of two signals varies with respect to each
other, i.e. it tests their synchrony. With random staining,
the ICQ (intensity correlation quotient) is ∼0; for dependent
staining 0 < ICQ+ 0.5, whereas for segregated staining
0 > ICQ− 0.5 [29]. Pre-existing defined immunofluorescence
images of random, dependent and segregated staining respectively
were used as controls.
PDM (product of the differences from the mean), i.e. for
each pixel, is defined as (Channel 1 intensity–Mean channel
1 intensity) × (Channel 2 intensity–Mean channel 2 intensity),
which is equal to the (A–a) × (B–b) described by Li et al. [29].
ICA plots represent the fluorescence intensities of one channel
as a function of the respective PDM values of both recording
channels.
The software for quantitative co-localization analysis was
provided as a plug-in (written by Elise Stanley, Toronto, ON,
Canada) to ImageJ.
FACI-50 GP (generalized polarization) measurements
The fluorescence emission properties of FACI-50 are sensitive
to the polarity of the local environment of the fluorescent probe
badan. Saturating amounts of CoA shift the maximum emission
yield of FACI-50 from 510 to 490 nm; acyl-CoA binding, in
contrast, causes a red-shift of FACI-50 emission [22]. Emission
spectral changes can be quantified comparing the GP values for
shifted and unshifted fluorescence intensity peaks of FACI-50.
GP values were calculated by: GP = Ib − Ig/Ib + Ig, where Ib and
Ig correspond to the intensities at the blue and green edges of
the emission spectrum respectively [30,31]. In vitro fluorescence
spectra were measured using a Chronos ISS fluorimeter (ISS,
Champaign, IL, U.S.A.) with a λex (excitation wavelength) of
374 nm using a laser diode as the excitation source. Ib and
Ig were measured at 470 and 520 nm respectively. Two-photon
excitation (800 nm) GP images of FACI-50-microinjected BMGE
cells in C-Hepes buffer covering 435–465 and 535–565 nm range
respectively were obtained simultaneously in dual-channel set-
up on a confocal microscope (model LSM 510 META; Carl
Zeiss MicroImaging). The objective used was a ×40/1.2 NA Plan
Apochromat water-immersion objective. The two images were
analysed using SimFCS software (Laboratory for Fluorescence
Dynamics) to obtain the GP image and the associated GP
histogram (distribution of the GP values per pixel).
Effect of defatted BSA and fatty acid addition on ACBP localization
FACI-50-microinjected BMGE cells prelabelled with BODIPY®
C5-ceramide as described above were incubated for 10 min in C-
Hepes buffer containing 600 µM FAFBSA (fatty-acid-free BSA)
or BSA complexed with 2.66 mM OA (oleic acid) (OA–BSA) to
give an OA/BSA molar ratio of 4.44, resulting in a free
OA concentration [FFAOA] of 150 nM as described previously
[32,33]. The OA–BSA complexes were made by mixing stock
solutions of 1.0 mM FAFBSA solution in C-Hepes with 50 mM
OA sodium salts dissolved in C-Hepes to give a final BSA
and OA concentration of 600 µM and 2.66 mM respectively
(OA/BSA ratio of 4.44) [33].
Two-photon excitation FRAP (fluorescence recovery after
photobleaching) experiments
To measure the mobility of FACI-50 in the Golgi complex of
BMGE cells treated with FAFBSA or the OA–BSA complexes
for 30 min, FRAP experiments were performed essentially as
described in [34]. Fluorescence recovery curves were fitted using
SigmaPlot scientific graphing software (Jandel Scientific, San
Rafael, CA, U.S.A.) and half-time recoveries were calculated as
described in [35].
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Figure 1 GFP–ACBP and GFP localization in vivo in HeLa cells
HeLa cells were stably transfected with the empty pEGFP-C1 vector (A) or GFP–ACBP (B). GFP
fluorescence was excited at 488 nm with a 30 mW Argon/2 laser and images were collected
using a primary HFT 488 dichroic beam splitter and a 505 nm long pass filter. The nuclei of
GFP-transfected cells were identified by incubating cells for 60 min with 16 µM DAPI dissolved
in C-Hepes buffer. DAPI was excited at 800 nm using two-photon excitation, which was reflected
by a primary HFT KP 650 dichroic mirror, fluorescence was filtered with a secondary NFT
490 dichroic mirror, and emission was recorded with a 435–485 nm band-pass filter. DIC,
differential interference contrast. All cell images were taken at 40× magnification as described
in the Experimental section.
CD spectroscopy
Far-UV CD spectra of recombinant bovine L-ACBP, FACI-50,
FACI-24 and Y28F/K32A-FACI-50 were recorded on a Jasco
J-810 spectropolarimeter scanning wavelengths in the range 250–
190 nm, averaging over 4–6 scans per experiment, data pitch of
0.1 nm and scan rate 20 nm/min at room temperature. Total protein
concentration was 10 µM and the proteins were diluted from
stocks into either Milli-Q water or 10 mM NaH2PO4 (pH 7.4).
The cuvettes used were 0.1 cm Quartz-Suprasil from Hellma.
Reference spectra of buffer or water were recorded during each
session and subtracted accordingly. Each sample was allowed at
least 10 min to reach equilibrium before spectrum acquisition.
RESULTS
A GFP–ACBP fusion protein expressed in HepG2 cells was found
to localize both to the cytoplasm and to the nucleus [21]. However,
no GFP expression control was reported in these experiments. We
explored the possibility of using stable expression of GFP–ACBP
to map the intracellular localization of ACBP in HeLa cells.
The results showed that localization of the GFP–ACBP cannot
be distinguished from that of GFP on its own (Figure 1). This
shows that the GFP–ACBP fusion is unsuitable for studying the
intracellular localization of basal 82–92-residue ACBP in vivo.
There might be several reasons for this. First, GFP in itself is
∼3.0 times larger than the ACBP and might therefore physically
hinder interaction of the ACBP–GFP fusion protein with potential
ACBP interaction partners. Secondly, GFP on its own has been
show to target to organelles including the nucleus [36]. This
could, if GFP is the dominating part of the fusion protein, provide
misleading results.
ACBP localizes to the ER and Golgi complex in HeLa cells
Fluorescence emission of FACI-50-injected HeLa cells shows
that bovine FACI-50 is highly concentrated close to the nucleus,
with moderate fluorescence intensity of the perinuclear membrane
typical for the localization to the Golgi and ER (results not
shown). The nucleus itself and the remaining cytosol show much
lower fluorescence emission intensities. Co-staining of FACI-50-
microinjected HeLa cells with the ER marker glibenclamide-
BODIPY® or the structural Golgi marker BODIPY® C5-ceramide
strongly indicates co-localization of ACBP both to the ER and to
the Golgi, with an ICQ of 0.193 and 0.135 respectively.
Although the sequences of bovine and human L-ACBP show
94% identity, it could be argued that the use of a bovine L-
ACBP-based probe in the human-derived HeLa cell line is non-
physiological. We therefore switched to the BMGE cell line.
Localization of ACBP to the ER and Golgi complex of BMGE cells is
ligand-dependent
In contrast with HeLa cells, BMGE cells represent a much
more homogeneously shaped cell population. BMGE cells are
morphologically large, very flat cells and, in the light microscope,
the nucleus and surrounding membranous organelles can be
clearly distinguished from the remaining cytosol. This makes
delivery of FACI-50 into the cytosol by microinjection easier
compared with HeLa cells, and thus significantly reduces the risk
of injection of the fluorescent probe into or near the nucleus,
which could lead to incorrect interpretation of ACBP localization
results.
Microinjection of FACI-50 into BMGE cells confirms that
ACBP localizes to the ER and Golgi, as seen in HeLa cells
(Figures 2A and 3A). In contrast, we were unable to show
co-localization of FACI-50 with mitochondria, lysosomes or
fat droplets when microinjection of FACI-50 into BMGE cells
incubated with MitoTracker Red CM-H2XRos, LysoTracker Red
DND-99 or the neutral lipid stain BODIPY® 493/503 respectively
was performed (see Supplementary Figures 1–3 at http://
www.BiochemJ.org/bj/410/0463/bj4100463add.htm). In order to
test the importance of ligand binding for association of ACBP with
the ER/Golgi, we produced by site-directed mutagenesis an FACI-
50 variant with impaired ligand binding ability, Y28F/K32A-
FACI-50. The Y28F/K32A site-directed mutations in yeast ACBP
have previously been shown to reduce dodecanoyl-CoA binding
of native bovine ACBP by approx. 1000-fold (J.S. Hansen, N.J.
Færgeman, B.B. Kragelund and J. Knudsen, unpublished work).
Isothermal titration microcalorimetry of FACI-24, FACI-
50 and Y28F/K32A-FACI-50 determined the dissociation
constant (Kd) of myristoyl-CoA binding to FACI-24 and
FACI-50 to be 62 +− 25 nM (n = 2) and 177 +− 52 nM (n = 3)
respectively. However, Y28F/K32A-FACI-50 could not be
shown to bind myristoyl-CoA at all (results not shown).
Fold integrity of all three FACI variants was confirmed from
far-UV CD spectral analysis (see Supplementary Figure 4
at http://www.BiochemJ.org/bj/410/0463/bj4100463add.htm),
demonstrating that the effect from mutations and fluorescence
labelling was directly on ligand binding and clearly not on
structure. The disruption of ligand binding activity strongly
perturbed the intracellular localization of ACBP, resulting in
an even distribution of Y28F/K32A-FACI-50 throughout the
whole cell including the nucleus (Figures 2B and 3B). The ICQs
for co-localization between ER staining and FACI-50 and
Y28F/K32A-FACI-50 staining were 0.30 and 0.038 respectively,
and between the Golgi and FACI-50 and Y28F/K32A-FACI-50
staining were 0.28 and −0.15 respectively. The low (0.038) or
negative (−0.15) ICQs for co-staining of Y28F/K32A-FACI-50
with the ER or with the Golgi respectively show that association
of the mutant protein with the ER is random and that it is
segregated from the Golgi. This suggests that ligand binding
targets ACBP to the ER/Golgi.
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Figure 2 ACBP localization with the ER in BMGE cells is function-dependent
Localization of microinjected FACI-50 (A, upper left panel) or Y28F/K32A-FACI-50 (B, upper left panel) and ER tracker glibenclamide-BODIPY® (A, B, upper middle panel), in BMGE cells. Merged
images are presented in upper right panels. Lower left panels show scatter plot of FACI-50 (A) and Y28F/K32A-FACI-50 (B) pixel staining intensities against ER tracker glibenclamide-BODIPY® pixel
staining intensities. Lower middle and right panels show individual fluorescence intensities of FACI-50 (A, lower middle panel), Y28F/K32A-FACI-50 (B, lower middle panel) or glibenclamide-BODIPY®
(lower right panels) plotted against their respective PDM values of both recording channels.
If this hypothesis holds, it should be possible to obtain similar
changes in FACI-50 intracellular localization by manipulating the
intracellular concentration of acyl-CoA levels. The intracellular
concentration of free fatty acids and acyl-CoA is strongly affected
by the concentration of free fatty acids in the media [32,37].
We therefore performed ICA measurements on FACI-50 co-
localization with the ER and Golgi in cells pre-incubated with
either FAFBSA or OA–BSA (molar ratio 4.44) in order to deplete
or overload respectively the cells with fatty acids. Addition of
FAFBSA to the medium caused a reduction in the ICA coefficient
for FACI-50 co-localization/association with the Golgi marker
from 0.128 +− 0.011 to 0.088 +− 0.009. On the contrary, addition
of OA–BSA resulted in an increased ICA coefficient for FACI-50
association with the Golgi from 0.088 +− 0.009 to 0.190 +− 0.013(Figure 4). This observation further supports the notion that ligand
binding is essential for targeting of ACBP to the Golgi. It should
be noted that the apparent overall lower ICQ of co-staining BMGE
cells with FACI-50 and BOPIPY® C5-ceramide in the BSA and
OA–BSA challenging experiments was due to an 8-fold increase
in image acquisition scan times, which reduces photobleaching
of the fluorophores but also lowers the image resolution.
To exclude the possibility that the ligand-dependent FACI-50–
Golgi interaction could be caused by the presence of badan on the
surface of FACI-50 in the ligand-bound state, the experiments
reported in Figure 4 were repeated with FACI-24, in which
the fluorophore is buried underneath acyl-CoA in the holo-
ACBP complex. FACI-24 exhibited the same ligand-dependent
interaction with the Golgi as FACI-50 (results not shown),
excluding that the FACI-50–acyl-CoA interaction with the Golgi
is caused by the badan side chain.
GP measurements of FACI-50 in vivo
Bovine L-ACBP binds free CoA with approx. 1000-fold lower
affinity (Kd≈2 µM [38]) than it binds palmitoyl-CoA (2–8 nM
[39]). Binding of CoA to FACI-50 causes a down-shift in
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 3 ACBP localizes to the Golgi in a ligand-binding-dependent manner
Localization of microinjected FACI-50 (A, upper left panel), Y28F/K32A-FACI-50 (B, upper left panel) and the Golgi marker BODIPY® C5-ceramide (A, B, upper middle panel) in BMGE cells.
Merged images are presented in the upper right panels. Lower left panels show scatter plots of FACI-50 (A) and Y28F/K32A-FACI-50 (B) pixel staining intensities against the Golgi marker BODIPY®
C5-ceramide pixel staining intensities. Lower middle and right panels show individual fluorescence intensities of FACI-50 (A, lower middle panel), Y28F/K32A-FACI-50 (B, lower middle panel) or
the Golgi marker BODIPY® C5-ceramide (lower right panels) plotted against their respective PDM values of both recording channels.
fluorescence emission maximum from 510 to 490 nm (Figure 5
and [22]). However, FACI-50 and FACI-50/oleoyl-CoA emission
spectra could not be differentiated. The calculated GP values
for the apo-FACI-50, FACI-50/oleoyl-CoA and FACI-50/CoA
in vitro spectra recorded in Figure 5 were −0.361 +− 0.001,−0.375 +− 0.004 and −0.004 +− 0.002 respectively. Therefore GP
measurements can be used to distinguish between FACI-50/CoA
and apo-FACI-50 plus acyl-CoA/FACI 50. The determined
in vivo GP value of −0.401 (Figure 5) was in the same range
as in vitro GP values of apo-FACI-50 (−0.361) and oleoyl-
CoA/FACI-50 (−0.375) respectively and significantly different
from the in vitro FACI-50/CoA GP value. This strongly suggests
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Figure 4 FAFBSA and OA–BSA challenging of FACI-50-injected BMGE cells
(A) FACI-50 (upper panels) and the Golgi marker BODIPY® C5-ceramide (lower panels)
localization in BMGE cells incubated successively for 10 min in C-Hepes buffer (left), C-Hepes
buffer containing FAFBSA (600 µM) and in C-Hepes buffer containing OA–BSA (molar ratio
0.6/2.64 mM, to give a calculated free OA concentration of 150 nM [32,33]). (B) The Figure
shows the ICQ values for FACI-50 fluorescence correlation with Golgi staining under the
conditions described above. Results are means +− S.D. (n = 5). Asterisk indicates statistically
significant differences (P < 0.001) between ICQ values obtained for cells in C-Hepes/FAFBSA
buffer relative to the same cells incubated in C-Hepes buffer and C-Hepes/OA–BSA buffer
respectively.
that ACBP in vivo is present as either apo-ACBP or acyl-CoA–
ACBP and not in complexes with CoA.
ACBP mobility in the Golgi is highly affected by endogenous fatty
acid levels
The fact that addition of OA–BSA to the incubation medium
results in increased co-localization with the Golgi (Figure 4),
combined with the fact that disruption of ligand binding capability
segregates FACI-50 from the Golgi, confirms the hypothesis that
ligand binding is essential and targets ACBP to the Golgi. This
notion is further supported by FRAP analysis, which showed
that the fluorescence recovery half-time of FACI-50 in the Golgi
complex of BMGE cells increased from 0.8 +− 0.4 s in C-Hepes
buffer to 3.7 +− 0.6 s in C-Hepes plus OA–BSA in the culture
medium (Figure 6). FRAP experiments on FACI-50-injected
BMGE cells incubated with FAFBSA did not alter ACBP mobility
compared with cells incubated in C-Hepes buffer alone (results not
shown). A 5-fold reduction in FACI-50 mobility in the presence of
OA–BSA in the culture medium strongly suggests that acyl-CoA
binding targets FACI-50 to the Golgi and that FACI-50 is actually
transiently associated with the Golgi.
DISCUSSION
Previous experimental data of the intracellular distribution
of ACBP using indirect immunofluorescence or immunogold
Figure 5 Normalized FACI-50 spectra and GP measurements in BMGE cells
(A) Normalized emission spectra of 1 µM FACI-50 in the absence (open squares) or presence
of saturating amounts of CoA (open triangles) or oleoyl-CoA (open diamonds). (B) Histogram
of whole cell GP measurements in FACI-50-injected BMGE cells.
electron microscopy have, as pointed out in the Introduction
section, yielded variable results from ACBP being exclusively
cytosolic in Leydig cells [11–13] or found in the nucleus only
of undifferentiated 3T3-L1 pre-adipocytes or in both the nucleus
and cytosol of differentiated 3T3-L1 cells [21]. In other cells, in-
cluding rat testes Leydig, Sertoli and seminiferous tubule cells,
ACBP distributed over the whole cytosol, but was also found
at the smooth ER, Golgi and outer membrane of mitochondria
[12]. In some cells, such as rat Stilling’s cells, ACBP was
concentrated around large cytoplasmic vesicles [17]. The value of
these previous experimental data may be questioned also due to
the technical problems mentioned above.
In the present study, we circumvented these difficulties by
performing live-cell imaging on microinjected fluorescently
labelled ACBP in HeLa and BMGE cells. The results show that
although ACBP was found throughout the whole cell, including
in the nucleus, it distributes in a very heterogeneous manner.
ACBP was found to be highly enriched on the ER, Golgi and
the perinuclear membrane, with lower concentrations seen in the
cytosol and in the nucleus, a finding that is in agreement with what
has previously been found by indirect immunohistochemistry
in rat hepatoma cells [7] and L-cell fibroblasts [20]. The co-
localization of FACI-50 with both the ER and Golgi was
confirmed by co-staining FACI-50-injected cells with organelle-
specific stains of these two compartments and calculating the ICQ
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Figure 6 FRAP of FACI-50 in the Golgi
An image was acquired of FACI-50-injected BMGE cells in C-Hepes buffer and cells were
incubated for 20 min with OA–BSA buffer (molar ratio 0.6/2.64 mM) respectively. A region of
interest (ROI) of the Golgi was photobleached for a very brief period by two-photon laser excitation
(45 % output) at 800 nm. Images were taken at different time points after photobleaching to
monitor the fluorescence recovery. After background correction, the ratio of the fluorescence
intensity in a photobleached region to the fluorescence intensity of the whole cell was calculated
for each time point. This ratio was divided by the corresponding ratio obtained from the
prebleaching image and presented as the percentage recovered. Each data point, derived from
an average of five experiments, was fitted to the equation y = y0 + a(1 − e−kt ), where k is
the rate constant, by using SigmaPlot scientific graphing software. Values are means +− S.D.
(n = 5). Half-time recoveries (t½) were calculated according to t½= ln(2)/k .
between the FACI-50 and organelle dye emission fluorescence.
The calculated ICQs for FACI-50 co-localization with the ER
and Golgi stains in BMGE cells suggest strong interaction with
both compartments. The Y28F/K32A-FACI-50 mutations, which
disrupt myristoyl-CoA binding, but retain the overall three-
dimensional structure of the protein, reduced the ICQ for co-
localization between the ER and Golgi staining from 0.30 and 0.28
for FACI-50 respectively to 0.038 and −0.15 for Y28F/K32A-
FACI-50 staining respectively, showing that Y28F/K32A-FACI-
50 no longer associates with the ER and segregates from the Golgi.
It has previously been shown that the intracellular concentration
of free fatty acids and acyl-CoA is strongly affected by the
concentration of free fatty acids in the media [32,37]. The present
study shows that ACBP is likely to occur as apo-ACBP or ACBP–
acyl-CoA, and not as ACBP–CoA complex in vivo. Increasing the
cellular concentration of acyl-CoA would therefore be expected to
increase the concentration of ACBP–acyl-CoA. If ligand binding
is required to target ACBP to the ER and Golgi, it should be
possible to alter ACBP association with the two organelles by
manipulating the fatty acid concentration in the culture media. Our
results show that this is indeed the case. Addition of FAFBSA to
the BMGE cell culture media, which will extract fatty acids from
the cells, reduced the ICQ for FACI-50 association with the Golgi
from 0.12 to ∼0.09, whereas addition of OA–BSA increased the
ICQ to ∼0.18 (Figure 4). The fact that addition of OA–BSA
to the media, in addition to increasing the ICQ, also reduced the
mobility of FACI-50 associated with the Golgi by 5-fold, as shown
by FRAP experiments (Figure 6), strongly supports the perception
that ligand binding targets ACBP to the Golgi.
The functional association of ACBP with both the ER and
Golgi opens new windows for interpretations of ACBP function in
relation to the existing published literature data. Long-chain acyl-
CoA synthetase activity is predominantly found on microsomes
(73%), mitochondria (20%) and in peroxisomes (7%) [40],
but not on the Golgi. Targeting of ACBP to the ER in a
ligand-dependent manner would therefore make sense, since
most of the acyl-CoA synthases and lipid-synthesizing acyl-
transferases are found on the ER. In this respect, it is interesting
that ACBP has been shown to co-localize with ACAT (acyl-
CoA:cholesterol acyltransferase) in the ER and perinuclear region
in L-cell fibroblasts [20]. The Golgi has not been reported to
contain acyl-CoA synthetase activity, but it has been reported
to harbour lysophospholipid acyltransferases that have been
suggested to co-ordinately regulate the Golgi membrane shape
and tubule formation [41] as well as protein acylation [42]. These
observations provide a possible explanation for the long-known
requirement of acyl-CoA for vesicle fusion and budding [43–
46]. The present result showing that ACBP gets targeted to the
Golgi in a ligand-dependent manner makes acyl-CoA–ACBP a
likely candidate for donating acyl-CoA esters required for budding
and fusion. Previous data show that Acb1p (ACBP)-depleted
yeast show all signs of perturbed vesicle trafficking, including:
(i) accumulation of numerous small vesicles in the cytosol, (ii)
appearance of fragmented vacuoles unable to fuse due to the lack
of essential SNARE proteins, (iii) appearance of multilayered
plasma membrane and (iv) induction of increased uptake of the
accumulating vesicles in the vacuole by micro-autophagocytosis
[4]. The observation that the C. elegans MAA-1 ACBP domain
protein participates in plasma-membrane endosomal vesicle
recycling confirms a role of ACBP proteins in donating acyl-CoA
required for fusion and budding of vesicles [6].
ACBP does not contain any specific organelle-targeting
sequences, except for a potential ER retrieval signal consisting
of a di-lysine (KK) motif near the C-terminus [47]. However,
this sequence motif is only conserved in a limited number
of mammalian basal ACBP isoforms [48]. The present results
show that this sequence motif on its own is unable to target
bovine L-ACBP to the ER and Golgi and that ligand binding
is essential and required to target FACI-50 to the Golgi. The
actual mechanism by which ACBP attaches to the membrane is at
present unknown. It has been reported that ACBP interacts with
charged lipids in a membrane-curvature-dependent manner [49].
However, these experiments were carried out at very low ionic
strength and cannot be repeated at physiological ionic strength
by using isothermal titration calorimetry (J.S. Hansen, N. J.
Færgeman, B.B. Kragelund and J. Knudsen, unpublished work).
Recent results obtained by atomic force microscopy have shown
that bovine L-ACBP–palmitoyl-CoA associates with DOPC (1,2-
dioleoyl-sn-3-glycerophosphocholine) linear membranes [3]. A
possible mechanistic explanation for this association could be an
exchange of the palmitoyl-acyl chain of the ACBP-bound acyl-
CoA with an oleoyl-acyl chain from a DOPC molecule in the
membrane. This would leave the CoA head group bound in the
binding site, with the palmitoyl-chain immersed in the DOPC
bilayer, stabilized by the phosphocholine-oleoyl chain flipping out
from the membrane and into the ACBP–acyl-CoA-binding site.
The observation that two human L-ACBP molecules have the
ability to share one intact dodecanoyl-CoA molecule having
the head group bound in one ACBP and the acyl-chain in the
other ACBP-binding site stabilized by a free fatty acid bound
in one ACBP and a 4-phosphopanteteine fragment in the other
ACBP [50] supports the above-suggested model for ACBP–acyl-
CoA membrane binding. Alternatively, ACBP could interact with
proteins residing in either the ER and/or the Golgi apparatus,
which is currently being investigated.
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